Pneumothorax another possible COVID-19 complication — Cambridge study

Organisation: Position: Deadline Date: Location:

As many as 1 in 100 hospitalised COVID-19 patients may experience a pneumothorax, or punctured lung, according to a multicentre observational case series. Pneumothorax usually occurs in very tall young men or older patients with serious underlying lung disease. But University of Cambridge researchers identified COVID-19 patients with neither of those traits who had a punctured lung or pneumomediastinum (air or gas leakage from a lung into the area between the lungs) from March to June at 16 UK hospitals.

“We started to see (COVID-19) patients affected by a punctured lung, even among those who were not put on a ventilator,” said Dr Stefan Marciniak, from the University of Cambridge. “To see if this was a real association, I put a call out to respiratory colleagues across the UK via Twitter. The response was dramatic – this was clearly something that others in the field were seeing.”

Sixty of 71 COVID-19 patients included in the study had a punctured lung, including two with different episodes of pneumothorax, for a total of 62 punctures. Six of the 60 patients with pneumothorax also had pneumomediastinum, while 11 patients had only pneumomediastinum.

Nine patients with shortness of breath on arrival at the hospital were diagnosed on chest x-ray as having punctured lung, 5 of them hospital re-admissions after COVID-19 treatment (4 patients) or becoming infected with coronavirus in the hospital (1). All patients in this group were older than 40 years, and only two had underlying lung disease.

Seven of the nine patients required a chest drain. Two (22%) died 7 and 10 days after pneumothorax, one not requiring a chest drain and one having had the drain removed after the pneumothorax healed. The remaining seven patients were released from the hospital after a median stay of 7 days.

Fourteen patients experienced pneumothorax during their hospitalization while breathing on their own on a general or respiratory ward; six of them were diagnosed by chance.

Three patients were on non-invasive ventilation at diagnosis. Eleven patients needed chest drains, while one required surgical intervention. Three patients (21%) died, the rest were released from the hospital after a median stay of 35 days, and one was later readmitted because of pneumothorax of the other lung.

Thirty-eight patients had a total of 39 lung punctures while receiving invasive ventilation; 26 needed invasive ventilation only, while 12 needed oxygen added to their blood outside their body.

Of the 26 patients requiring only invasive ventilation, punctured lung was diagnosed by chance or because they needed more oxygen, revealing hypercapnia (excess carbon dioxide caused by breathing that is too shallow or slow) and acidosis, a build-up of acid caused by lung or kidney dysfunction. Seven patients were given a chest drain, and eight survived for at least 28 days.

There was no significant difference in 28-day survival after punctured lung or pneumomediastinum (63.1% vs 53%; P = 0.85) or between men and women (62.5% vs 68.4%, P = 0.62). However, men were three times more likely to have pneumothorax than women, which the authors said might be because men with COVID-19 appear predisposed to more severe disease. No patients required treatment for pneumomediastinum.

Patients 70 years and older had only a 41.7% survival rate, compared with 70.9% in younger patients (P = 0.02), and patients with acidosis had only a 35.1% chance of 28-day survival, versus 82.4% of their peers, regardless of age.

The authors noted that previous small retrospective studies suggested that punctured lungs might occur in 1% of hospitalised COVID-19 patients and those dying from their infections and 2% of those needing intensive care, while another study estimated rates of barotrauma (both pneumothorax and pneumomediastinum) at 15%.

A case report out of China highlights the importance of being on guard for spontaneous pneumothorax, or sudden collapsed lung, especially in COVID-19 patients who have prolonged severe lung damage.

Studies have also suggested that other coronaviruses may contribute to pneumothorax.

The authors of the new study said that COVID-19 may cause cysts in the lungs that could lead to lung punctures. They advised doctors to consider the possibility of punctured lungs in COVID-19 patients, even in those who don’t fit the profile for it, as many study patients were diagnosed with this condition only by chance.

While an observational case series can’t prove that COVID-19 causes pneumothorax, the authors said that the number of affected patients in their study make it unlikely that all lung punctures were coincidental. They said that if there were no link between the two conditions, they would likely have observed only 18 cases of punctured lung in COVID-19 patients from 22 January to 3 July.

While previous studies have suggested that pneumothorax is a predictor of poor outcomes, the authors noted that study patients had an overall 63.1% survival rate and that 52% were released from the hospital.

“These cases suggest that pneumothorax is a complication of COVID-19,” they wrote. “Pneumothorax does not seem to be an independent marker of poor prognosis and we encourage active treatment to be continued where clinically possible.”

Co-author Dr Anthony Martinelli, a respiratory physician at Broomfield Hospital, said: “Although a punctured lung is a very serious condition, COVID-19 patients younger than 70 tend to respond very well to treatment. Older patients or those with abnormally acidic blood are at greater risk of death and may therefore need more specialist care.”

Abstract
Introduction: Pneumothorax and pneumomediastinum have both been noted to complicate cases of COVID-19 requiring hospital admission. We report the largest case series yet described of patients with both these pathologies that includes non-ventilated patients.
Methods: Cases were collected retrospectively from UK hospitals with inclusion criteria limited to a diagnosis of COVID-19 and the presence of either pneumothorax or pneumomediastinum. Patients included in the study presented between March and June 2020. Details obtained from the medical record included demographics, radiology, laboratory investigations, clinical management and survival.
Results: Seventy-one patients from 16 centres were included in the study, of whom 60 patients had pneumothoraces (six also with pneumomediastinum), whilst 11 patients had pneumomediastinum alone. Two of these patients had two distinct episodes of pneumothorax, occurring bilaterally in sequential fashion, bringing the total number of pneumothoraces included to 62. Clinical scenarios included patients who had presented to hospital with pneumothorax, patients who had developed pneumothorax or pneumomediastinum during their inpatient admission with COVID-19 and patients who developed their complication whilst intubated and ventilated, either with or without concurrent extracorporeal membrane oxygenation. Survival at 28 days was not significantly different following pneumothorax (63.1%±6.5%) or isolated pneumomediastinum (53.0%±18.7%; p=0.854). The incidence of pneumothorax was higher in males. The 28-day survival was not different between the sexes (males 62.5%±7.7% versus females 68.4%±10.7%; p=0.619). Patients above the age of 70 had a significantly lower 28-day survival than younger individuals (≥70 years 41.7%±13.5% survival versus <70 years 70.9%±6.8% survival; p=0.018 log-rank).
Conclusion: These cases suggest that pneumothorax is a complication of COVID-19. Pneumothorax does not seem to be an independent marker of poor prognosis and we encourage active treatment to be continued where clinically possible.

Authors
Anthony W Martinelli, Tejas Ingle, Joseph Newman, Iftikhar Nadeem, Karl Jackson, Nicholas D Lane, James Melhorn, Helen E Davies, Anthony J Rostron, Aldrin Adeni, Kevin Conroy, Nicholas Woznitza, Matthew Matson, Simon E Brill, James Murray, Amar Shah, Revati Naran, Samanjit S Hare, Oliver Collas, Sarah Bigham, Michael Spiro, Margaret M Huang, Beenish Iqbal, Sarah Trenfield, Stephane Ledot, Sujal Desai, Lewis Standing, Razeen Mahroof, Ian Smith, Kai Lee, Nairi Tchrakian, Stephanie Uys, William Ricketts, Anant RC Patel, Avinash Aujayeb, Maria Kokosi, Alexander JK Wilkinson, Stefan J Marciniak

 

CIDRAP material

 

European Respiratory Journal abstract

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.